PHOENIX All-in-One

Belkins
All-in-One: Our expertise and coverage for the success of manufacturer partners to provide manufacturer partners a unified approach to the European and all 26 local markets, the PHOENIX group has brought the service brand “All-in-One” into life. All-in-One grants a direct access for manufacturers to patients. With its eight focus areas from a Pan-European Preferred Partnerships, Healthcare Logistics, Business Intelligence, Patient Services to Supply Chain Optimization, Sales Support, Clinical Trial Supply Services and Services for Specialty Drugs, All-in-One has an unparalleled service to manufacturer partners throughout Europe. You do your core business – we care about the rest Our full-service offering enables manufacturers to focus on their core competencies – developing and successfully commercializing innovative products and solutions. We care about the rest. “All-in-One is more than just a collection of services, it is a unified approach to patients all over Europe”, says Stefan Jung, Head of Pharma Services at PHOENIX group.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CANNABIS INDUSTRY GIANT WAYOFLEAF.COM EXPANDS HEALTH-SPECIFIC CONTENT, INTRODUCES MEDICAL REVIEW TEAM

Prnewswire | September 30, 2020

news image

In a bid to improve the quality and availability of information on health-specific cannabis use, industry giant WayofLeaf.com has introduced a team of doctors and health experts to review thousands of topics relating to the use of medical cannabis and CBD for specific health conditions. The website, which for years has provided a reliable informational resource for medical cannabis patients, believes it is time for cannabis users of all types to have access to trustworthy, research-backed conten...

Read More

PHARMA TECH

VEEVA DEVELOPMENT CLOUD SIMPLIFIES DRUG DEVELOPMENT IN THE INDUSTRY

Veeva Systems | May 21, 2021

news image

A growing number of life sciences companies are adopting Veeva Development Cloud applications from Veeva Systems in an industrywide shift to streamline drug development. quite 650 companies use Veeva Development Cloud applications today, and quite 250 are leveraging multiple Veeva Vault applications across functional areas to enable and connect drug development and manufacturing teams. Veeva Development Cloud brings together suites of unified applications for clinical, regulatory,...

Read More

PFIZER CONTINUES RECALLS OF MENOPAUSE DRUG DUAVEE ON FAULTY PACKAGING CONCERNS

Fiercepharma | June 09, 2020

news image

Consumers are on edge as the COVID-19 pandemic casts doubts on the quality of drugs reaching shelves around the world. On U.S. shores, experts say those issues are warranted—and a wave of Pfizer recalls for menopause drug Duavee won't help build confidence. Pfizer voluntarily recalled two batches of Duavee––marketed as Duavive abroad––from U.K. shelves after identifying faulty packaging that may have reduced the drug's efficacy, the U.K.'s Medicines and ...

Read More

ASTELLAS, CYTOMX FORM T-CELL ENGAGING CANCER ANTIBODIES PARTNERSHIP

PharmaTimes | March 26, 2020

news image

Astellas has entered into a new partnership with CytomX Therapeutics, in order to develop T-cell engaging bispecific antibodies targeting CD3 and tumour cell surface antigens for the treatment of cancer. The companies have revealed that the deal, which is potentially worth more than $1.6 billion, will focus on several initial programmes, with CytomX leading research and discovery activities, up to clinical candidate selection, which will be funded by Astellas. As part of the deal, Astellas has c...

Read More

Prnewswire | September 30, 2020

news image

CANNABIS INDUSTRY GIANT WAYOFLEAF.COM EXPANDS HEALTH-SPECIFIC CONTENT, INTRODUCES MEDICAL REVIEW TEAM

In a bid to improve the quality and availability of information on health-specific cannabis use, industry giant WayofLeaf.com has introduced a team of doctors and health experts to review thousands of topics relating to the use of medical cannabis and CBD for specific health conditions. The website, which for years has provided a reliable informational resource for medical cannabis patients, believes it is time for cannabis users of all types to have access to trustworthy, research-backed conten...

Read More

PHARMA TECH

Veeva Systems | May 21, 2021

news image

VEEVA DEVELOPMENT CLOUD SIMPLIFIES DRUG DEVELOPMENT IN THE INDUSTRY

A growing number of life sciences companies are adopting Veeva Development Cloud applications from Veeva Systems in an industrywide shift to streamline drug development. quite 650 companies use Veeva Development Cloud applications today, and quite 250 are leveraging multiple Veeva Vault applications across functional areas to enable and connect drug development and manufacturing teams. Veeva Development Cloud brings together suites of unified applications for clinical, regulatory,...

Read More

Fiercepharma | June 09, 2020

news image

PFIZER CONTINUES RECALLS OF MENOPAUSE DRUG DUAVEE ON FAULTY PACKAGING CONCERNS

Consumers are on edge as the COVID-19 pandemic casts doubts on the quality of drugs reaching shelves around the world. On U.S. shores, experts say those issues are warranted—and a wave of Pfizer recalls for menopause drug Duavee won't help build confidence. Pfizer voluntarily recalled two batches of Duavee––marketed as Duavive abroad––from U.K. shelves after identifying faulty packaging that may have reduced the drug's efficacy, the U.K.'s Medicines and ...

Read More

PharmaTimes | March 26, 2020

news image

ASTELLAS, CYTOMX FORM T-CELL ENGAGING CANCER ANTIBODIES PARTNERSHIP

Astellas has entered into a new partnership with CytomX Therapeutics, in order to develop T-cell engaging bispecific antibodies targeting CD3 and tumour cell surface antigens for the treatment of cancer. The companies have revealed that the deal, which is potentially worth more than $1.6 billion, will focus on several initial programmes, with CytomX leading research and discovery activities, up to clinical candidate selection, which will be funded by Astellas. As part of the deal, Astellas has c...

Read More